Company: RNAC
Filing Date: 2025-12-18
Form Type: 8-K
Source: 0001453687-25-000140
Chunk: 0

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-12-18
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2025, the Board of Directors (the “ Board”) of Cartesian Therapeutics, Inc. (the “ Company”) appointed Adrian Bot, M. D., Ph. D. as a Class II director. Dr. Bot has been appointed to serve until the Company’s annual meeting of stockholders to be held in 2027 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal. Dr. Bot initially will serve on the Science and Technology Committee of the Board.

Dr. Bot, age 57, is a biopharma executive with three decades of experience in research and development with a focus on immune, cell, gene therapy and nanomedicines. Most recently, he was the founding Chief Scientific Officer and Executive Vice President of R& D at Capstan Therapeutics, a company developing next generation RNA-based precision medicines. Previously, he held leadership roles at Kite Pharma and Kite, a Gilead Company, including Chief Scientific Officer, Global Head of Translational Medicine and Head of Discovery Research, respectively. At Kite, he contributed to the development of first-in-class CAR T cell therapy products for cancer. Dr. Bot also served in various senior R& D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. He obtained his M. D. in Romania in 1993, his Ph. D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998 and subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California.

Dr. Bot is eligible to participate in the Company’s Non-Employee Director Compensation Plan, which provides for (i) annual retainers of $40,000 for his Board service and $7,500 for his Science and Technology Committee service, (ii) an initial award of an option (the “ Option”) to purchase 17,200 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock”), and (iii) an initial award of restricted stock units (the “ RSUs”) that may be settled for 5,800 shares of Common Stock. The Option has an exercise price equal to $8.29 per share, the fair market value of a share of the Common Stock on the date